Sell to hold by Hunting Alpha. "The valuations of PFE stock are near trough levels and suggesting undervaluation vs peers.

Pfizer Inc. and BioNTech SE failed to knock out any of Alnylam Pharmaceuticals Inc.’s patents in a case over the partners’ Covid-19 vaccines, as a federal judge said he made no findings that would let ...

Three Native American healthcare facilities to benefit from pharmaceutical giant’s contribution aimed at boosting services ...

Q1 2025 Earnings Call Transcript April 29, 2025 Pfizer Inc. beats earnings expectations. Reported EPS is $0.92, expectations ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer. Pfizer should be able to easily fund an acquisition of either small drugmaker. The ...

The company expects to save an additional $1.2 billion from automation, AI and other digital tools.

Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...

A series of multibillion-dollar acquisitions has yet to yield new blockbusters, and Pfizer’s stable of drugs in development ...

Most appealing to long-term investors is that Pfizer stock is trading near its decade-long low in terms of price to forward earnings at 7.7X and well below the high of 20.1X during this period. PFE ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.